Literature DB >> 33728743

miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.

Li Jiang1, Yong Zhang1, Bo Li1, Min Kang1, Zhendong Yang1, Chunyu Lin2, Kai Hu1, Zhuxin Wei1, Meng Xu1, Jinglin Mi1, Rensheng Wang1, Fang Wu1.   

Abstract

The microRNAs (miRNAs) in circulating small extracellular vesicles (sEVs) have been suggested as potential biomarkers in cancer diagnosis. This study was designed to evaluate the circulating sEV-derived miRNAs as biomarkers for the diagnosis of nasopharyngeal carcinoma (NPC). We compared the miRNA profiles in plasma-derived sEVs between 16 patients with NPC and 5 healthy controls (HCs). A distinct set of miRNAs that were differentially expressed between patients with NPC and HCs was determined by means of integrative bioinformatics approaches. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis revealed that the target genes of the differentially expressed miRNAs (DEMs) were mainly involved in cancer-associated signaling pathways. Seven representative DEMs were selected and further validated in an additional 60 patients with NPC and 40 HCs using quantitative reverse-transcription PCR analysis (qRT-PCR). Receiver operating characteristic (ROC) curve analysis was used to assess the accuracy of the sEV-miRNA-based model for diagnosis. The 3 miRNA-based model, comprising miR-134-5p, miR-205-5p, and miR-409-3p, showed good discriminating power with an area under the curve (AUC) value of 0.88 in the training set and 0.91 in the validation set. Furthermore, the diagnostic model had an excellent classification ability to distinguish patients with NPC at different clinical stages or Epstein-Barr virus infection status from HCs. In conclusion, our findings indicated that sEV-derived miRNA levels were altered in the plasma of patients with NPC in comparison with those in HCs. The model based on the 3 sEV-derived miRNAs could potentially act as an alternative or complementary approach for diagnosing NPC.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  biomarker; diagnosis; microRNA; nasopharyngeal carcinoma; small extracellular vesicle

Year:  2021        PMID: 33728743     DOI: 10.1111/cas.14883

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  4 in total

Review 1.  Extracellular Vesicles in the Progression and Therapeutic Resistance of Nasopharyngeal Carcinoma.

Authors:  Yunhan Shan; Peijun Zhou; Qin Zhou; Lifang Yang
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

2.  Identification of a five-miRNA signature as a novel potential prognostic biomarker in patients with nasopharyngeal carcinoma.

Authors:  Bo Tu; Ling Ye; Qingsong Cao; Sisi Gong; Miaohua Jiang; Hui Li
Journal:  Hereditas       Date:  2022-01-08       Impact factor: 3.271

Review 3.  Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.

Authors:  Hai-Long Li; Nian-Hua Deng; Xiu-Sheng He; Yue-Hua Li
Journal:  Biomark Res       Date:  2022-07-26

4.  The CBP/β-Catenin Antagonist, ICG-001, Inhibits Tumor Metastasis via Blocking of the miR-134/ITGB1 Axis-Mediated Cell Adhesion in Nasopharyngeal Carcinoma.

Authors:  Luo Chen; Yiu Chun Chiang; Lai Sheung Chan; Wai Yin Chau; Maria Li Lung; Michael Kahn; Kwok Wai Lo; Nai Ki Mak; Hong Lok Lung
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.